Ionis & GSK Report Positive Phase 3 Results for Bepirovirsen
– Primary endpoint met in both trials –– Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate –– Chronic hepatitis B (CHB) accounts for ~56% of...